Humasis Co. Ltd. (KOSDAQ:205470)
South Korea · Delayed Price · Currency is KRW 1,393.00
+6.00 (0.43%)
Sep 18, 2025, 3:30 PM KST
Humasis Revenue
Humasis had revenue of 8.88B KRW in the quarter ending June 30, 2025, with 708.44% growth. This brings the company's revenue in the last twelve months to 37.49B, up 278.47% year-over-year. In the year 2024, Humasis had annual revenue of 25.41B with 83.79% growth.
Revenue (ttm)
37.49B
Revenue Growth
+278.47%
P/S Ratio
4.19
Revenue / Employee
543.32M
Employees
69
Market Cap
156.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.41B | 11.59B | 83.79% |
| Dec 31, 2023 | 13.83B | -457.45B | -97.07% |
| Dec 31, 2022 | 471.27B | 149.44B | 46.44% |
| Dec 31, 2021 | 321.83B | 276.11B | 603.96% |
| Dec 31, 2020 | 45.72B | 36.57B | 399.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |